Kornimate/medical-research-clean huggingface dataset:
the effect of phenolic compounds in osteoarthritis; a nutritional intervention

Conditions: Symptomatic Knee Osteoarthritis

Summary: the main objective of the study is to elucidate the beneficial effect of a dietary supplement with phenolic compounds in patients with oa versus ascorbic acid. the analysis of the data is expected to clarify the role of the new supplement as one with a positive effect on oa-related biomarkers, on functional abilities and on the quality of life of patients with oa.


Eligibility criteria:
inclusion criteria: * symptomatic knee oa (patients with at least moderate symptoms) * patients should be able to walk without a medical or other support device (such as a walking stick, crutches, or a kneecap). exclusion criteria: * patients undergoing physical therapy or tens, have rheumatoid arthritis, fibromyalgia, spinal disorders or any other disorders that according to the physician is a bias, stiffness\> 30 minutes, have scheduled knee surgery or any other programmed surgery during the trial, show womac pain scale \<4 for pain overall, those with a diagnosis of kidney or liver disease, coagulation disorders, any form of cancer, hiv infection, type i diabetes, those with unregulated type ii diabetes, those using illicit substances or having a history of substance or alcohol abuse over the past 2 years (or those who consume more than 2 typical alcoholic beverages / day in the present), those using corticosteroids within 2 months prior to randomization and during the trial, those who change their diet or supplementation 1 month or during the recruitment/trial, those using ascorbic acid supplement or any phytochemical-rich supplement, women on estrogen replacement therapy, during pregnancy or lactation and those judged by the researcher as unable to perceive and comply with the obligations laid down in the protocol and for which consent and voluntary participation is sought.

Keywords: symptomatic knee osteoartritis, phenolic compound,
study to determine pediatric bladder volume prior to catheterization

Conditions: Urinary Tract Infection

Summary: this is a randomized controlled trial evaluating the effectiveness of bedside volumetric bladder ultrasound prior to transurethral catheterization of pediatric patients presenting to an emergency department with suspected urinary tract infection. ultrasound prior to catheterization allows emergency physicians to determine if the urine volume of the bladder is sufficient for successful catheterization. advance knowledge of insufficient urine allows the emergency physician to defer the procedure until success is likely.


Eligibility criteria:
inclusion criteria: * children 0-36 months of age * require urethral catheterization for urine analysis exclusion criteria: * recently voided and unlikely to provide sufficient urine when catheterized * documented or suspected genitourinary abnormalities precluding urethral catheterization * indwelling catheter or urostomy * critical illness * no available legal guardian or legal guardian does not understand english well enough to provide informed consent * technical failure of the utlrasound equipment

Keywords: urethral catheterization emergency department ultrasound urinary tract infection pediatric
a multi-modal approach to addressing cardiovascular risk and building resilience in youths with psychosis

Conditions: Schizophrenia; Psychotic Disorders

Summary: the purpose of this study is to determine the feasibility (≥ 50% completion rate) of a 6-week nutrition, movement, and mindfulness program for youth with recent diagnosis of psychosis.

the purpose of this study is to determine the feasibility of a 6-week nutrition, movement, and mindfulness program (m³ program) for youth with a recent diagnosis of psychosis. program effects on metabolic and mental health outcomes compared to wait-list control will also be assessed. participants will be 15-25 years of age, and have a recent diagnosis of psychosis. twenty participants and their study partners (20 study partners) will be equally divided into two cohorts. participants will sign up for one of the two series on a rolling enrollment basis until both of the program date frames are filled. participants that signed up for the second series will serve as a wait-list control; outcomes from the participants in the first series will be compared to this group. m³ will be a combination of didactic and experiential training. the course will meet once-a-week for six weeks. participants will learn how to prepare healthy snacks and meals, make healthy choices when eating out, and interpret food packaging and labels. they will also learn about different forms of mindfulness exercises and movement, such as yoga, martial arts, and a japanese style of drumming. feasibility will be assessed throughout the program.

Eligibility criteria:
inclusion criteria: * first diagnosis of psychosis occurs within 3 years of enrollment into the study or are a graduate of the early assessment and support alliance program (easa). * established mental health provider and primary care physician. * age 15 to 25 years (inclusive) * able to enroll with a study partner (study partner can be a healthy volunteer) * able to read and write in english exclusion criteria: * active suicidal or homicidal thoughts * mental status exam which suggests high risk for disruptiveness to group process or danger to self and others. * if a graduate of easa, the participant must have a primary care or mental health provider.
staphylococcus lugdunensis prosthetic joint infection

Conditions: Staphylococcal Infections; Prosthetic Joint Infection

Summary: staphylococcus lugdunensis is a coagulase-negative staphylococcus belonging to the human commensal cutaneous flora, and has been little studied in the field of prosthetic joint infections. however, it shares many virulence traits with staphylococcus aureus, including many adhesins and its ability to form biofilm, and the few series of cases reports a significant failure rate.


Eligibility criteria:
inclusion criteria: * infection of joint prosthesis (whatever its type) with staphylococcus lugdunensis defined by the positivity of at least 2 gold-standard samples (joint puncture, intraoperative samples) with s. lugdunensis; or * a single positive gold-standard sample or positive blood cultures and formal clinical, radiological, biological and / or pathological arguments in favor of an infection of joint prosthesis and absence of other pathogenic agent exclusion criteria: * none

Keywords: staphylococcus lugdunensis prosthetic joint infection biofilm
managing cancer and living meaningfully (calm): a study to evaluate the effectiveness of a psychological intervention for cancer patients

Conditions: Depression

Summary: the purpose of this study is to test the effectiveness of a brief manualized individual psychotherapy, called managing cancer and living meaningfully (calm), to reduce distress and promote psychological well-being in patients with various types of cancer, including metastatic disease.

we have developed and pilot-tested a brief manualized individual psychotherapy, called managing cancer and living meaningfully (calm), to reduce distress in patients with various types of cancer, including metastatic disease. we propose to conduct a two-arm randomized controlled trial (rct) to test the effectiveness of calm against usual care (uc) for the reduction of distress in patients with various types of cancer, including metastatic disease. usual care at our center includes routine screening for depression and other distress in oncology outpatient clinics, communication of screening information to the medical treatment team, and referral as needed for non-standardized, and primarily instrumental, psychosocial care and psychiatric assessment and treatment. the design will be an unblinded rct consisting of two conditions (calm and uc), with a baseline assessment and follow-ups at three and six months. the trial will take place in princess margaret cancer centre, university health network, a comprehensive cancer center in toronto, canada. participants will be outpatients with various types of cancer, including metastatic disease.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * fluency in english * confirmed diagnosis of stage iii or iv lung cancer; any stage of pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary/peri-ampullary cancer, or other stage iv (metastatic) gastrointestinal cancer; stage iii or iv ovarian and fallopian tube cancers, or other stage iv gynecological cancers; and stage iv breast, genitourinary, sarcoma, melanoma or endocrine cancers (all with expected survival of 12-18 months) exclusion criteria: * major communication difficulties (including language barriers) * inability to commit to the required 3-6 psychotherapy sessions * cognitive impairment indicated in the medical record, or by the attending oncologist, or as indicated by a score \< 20 on the short orientation-memory-concentration test, unless deemed suitable at the recruiter's discretion * actively seeing a psychiatrist or psychologist in the department of supportive care (formerly the department of psychosocial oncology and palliative care) at princess margaret cancer centre at the time of study approach

Keywords: randomized controlled trial depression cancer psychotherapy quality of life
active surveillance in prostate cancer, imaging to detect radiographic progression as an endpoint (aspire)

Conditions: Prostate Cancer

Summary: the objective in this study is to determine if mri-identified progression can decrease frequency or need for repeated prostate biopsy in men on active surveillance (as). our hypothesis is that mri alone is adequate to detect progression of prostate cancer in men on active surveillance (as) after a mri-us fusion prostate biopsy.

mri fusion prostate biopsy will transform active surveillance (as) for men with low risk prostate cancer. treatment for prostate cancer, usually surgical removal or radiation delivered to the whole prostate, is associated with significant morbidity including incontinence and impotence. the goal of this and future research is to maximize the effectiveness of prostate imaging in order to minimize the morbidity of prostate biopsy and hence improve the quality of life of patients with prostate cancer. there are many applications to improved imaging of prostate cancer, but several the investigators are interested in include: improved risk stratification to limit unnecessary treatment while providing appropriate treatment to prevent progression; limiting the number of biopsies needed for diagnosis and/or decreasing the frequency of biopsies and hence decreasing biopsy-related morbidity; focal therapy for confirmed focal disease rather than treating the entire prostate in order to limit the significant morbidity associated with whole-gland treatment. this is an investigator-initiated, multi-center, prospective observational phase ii trial evaluating mri to detect prostate cancer progression in patients with low risk prostate cancer on active surveillance. the two centers involved will be the yale-new haven hospital smilow cancer center (yale) and the va connecticut healthcare system (vact). the yale school of medicine will serve as the central data-coordinating center for this study.

Eligibility criteria:
inclusion criteria: * age 30-80 * completed mri fusion prostate biopsy either in the past that demonstrated gleason 6 prostate cancer and are either currently enrolled in active surveillance or are interested in active surveillance, or have completed an mri fusion prostate biopsy at the first visit that demonstrates gleason 6 prostate cancer and are interested in active surveillance * diagnosed with gleason 6 prostate cancer * psa \<20 * \<ct3 prostate cancer * ability to receive an mri with iv gadolinium contrast * life expectancy \>10 years (by physician estimate) * understanding and willingness to provide consent * english speaking exclusion criteria: * received treatment for prostate cancer (hormone manipulation, surgery, radiation). * known metastatic disease * high risk prostate cancer by epstein criteria * any gleason 7 or higher prostate cancer on prostate biopsy * inability to receive an mri with iv gadolinium contrast * life expectancy \<10 years * unwillingness to undergo monitoring and imaging studies * non-english speaking
comparison of the safety and efficacy of intravenous iron versus oral iron in subjects who display postpartum anemia

Conditions: Anemia

Summary: this study compares the safety and efficacy of intravenous iron vs oral iron in subjects who display postpartum anemia.

this is an open label, phase iii, randomized, active controlled study of intravenous iron vs oral iron in anemic post partum patients.

Eligibility criteria:
inclusion criteria: * female subjects able to give consent * post partum patients * baseline hbg\< /= 10 * agree to practice birth control * demonstrate willingness to comply with protocol restrictions exclusion criteria: * known hypersensitivity reaction to oral or iv iron (vit-45) * documented history of discontinuing oral iron * significant bleeding * history of anemia other that iron deficiency anemia * severe psychiatric disorders * active severe infection * known hepatitis b antigen or hep c viral antibody or active hepatitis * known hiv antibody * received investigational product within 30 days * alcohol abuse * hemochromatosis or other iron storage disorder

Keywords: anemia postpartum postpartum anemia
combined optical and infrared imaging for early prediction of erythema during breast and chestwall radiotherapy

Conditions: Breast Cancer

Summary: the aim of this study is to develop a computer model, based on photographs and heat images of patients' skin, to provide early prediction of painful reddening of the skin during radiotherapy treatment.

there is currently no reliable tool to quantify and detect erythema of the skin during radiotherapy. this side-effect may lead to painful moist desquamation, and eventually permanent delayed side effects like telangiectasia. if such a tool would be available, several interventions could be staged, including (1) the use of steroid cream\], (2) the re-simulation and/or re-planning of patients to decrease the skin dose by spreading out the entrance of the beams, (3) adjusting or eliminating the use of bolus on the skin surface (which boosts superficial dose) or (4) the use of other treatment techniques including prone technique. given that the dose delivered is not a reliable metric to predict for erythema in a given patient, a new method for monitoring, staging and ultimately predicting skin response is needed. by analyzing images of the skin using both visible and infrared spectral regions, and by carefully converting the information in the images to quantitative metrics, it may be possible to characterize the stage of a patient's response to radiation, and to understand which patients may go on to experience chronic pain, severe burns or other more serious side effects while it is still early enough to intervene. the proposed research is to develop a software model that will take as input patient skin image data and the patient known clinical outcomes and algorithmically generalize a model to predict a biological response of skin to ionizing radiation for any future patient, after a few initial images. in the first stage of this study, the data will be aggregated to devise the dose response curve. in later phases, the model will be refined and used for predictive purposes, i.e., once a new patient has begun radiotherapy sessions, their initial response will be quantified, and fed into the model to predict the skin response endpoint after the course of radiation therapy ends. as mentioned, this information could be used to adapt the radiation course and optimize the therapy for the individual, potentially preventing morbidity from overdose, or risk of recurrence from under dose.

Eligibility criteria:
inclusion criteria: - all female patients referred for adjuvant radiotherapy following breast conserving surgery/mastectomy. exclusion criteria: * patients with known skin issues (e.g. dermatomyositis, rosacea) * patients with excessive risk of skin recurrence, including t4d * patients with locally advanced breast cancer.
monitoring epstein-barr virus (ebv) load in rheumatoid arthritis patients treated with new immunosuppressive drugs

Conditions: Rheumatoid Arthritis

Summary: pbmnc dna is considered a limit above which patients will develop ebv associated post transplant lymphoproliferative disorder. we showed that methotrexate tended to decrease ebv load over time, but this did not reach significance and that tnfa inhibitors did not significantly modify ebv load over time. our objective is to monitor epstein barr virus load over time in patients with rheumatoid arthritis under orencia\* (abatacept) or roactemra\* (tocilizumab), to detect possible immunosuppression associated ebv dysregulation, as seen in post transplant lymphoproliferative disease.

current treatment of ra routinely includes potentially immunosuppressive medications like methotrexate and tnfa inhibitors. new immunosuppressive drugs are at disposal, orencia\* (abatacept) which is a t cell co-stimulation modulator (ctla4ig) and roactemra\* (tocilizumab), an antibody against il6 receptor. in solid organ transplant recipients under immunosuppressants, emergence of lymphoma can be predicted by monitoring ebv load in peripheral blood mononuclear cells (pbmncs). ebv load above 1000 copies per 500 ng pbmnc dna is considered a limit above which patients will develop ebv associated post transplant lymphoproliferative disorder, a condition characterized by polyclonal ebv positive b lymphocyte proliferation which can evolve into ebv positive b cell lymphoma . in a first study, we showed that rheumatoid arthritis patients have 10 fold systemic ebv overload, very similar to that observed in healthy organ transplant recipients. more recently, we showed that methotrexate tended to decrease ebv load over time, but this did not reach significance and that tnfa inhibitors did not significantly modify ebv load over time. our objective is to monitor epstein barr virus load over time in patients with rheumatoid arthritis under orencia\* (abatacept) or roactemra\* (tocilizumab), to detect possible immunosuppression associated ebv dysregulation, as seen in post transplant lymphoproliferative disease.

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis patients * treated with new immunosuppressive drugs : orencia\* (abatacept) and roactemra\* (tocilizumab) * disease longer than one year exclusion criteria: * rheumatoid arthritis patients treated with ciclosporin in two years preceding the study * transplanted patients * disease shorter than one year * histories of lymphoma

Keywords: rheumatoid arthritis patients treated with new immunosuppressive drugs : orencia* (abatacept) and roactemra* (tocilizumab).
ctop/ite/mtx compared with chop as the first-line therapy for newly diagnosed young patients with t cell lymphoma

Conditions: ALK-negative Anaplastic Large Cell Lymphoma; Peripherial T Cell Lymphoma,Not Otherwise Specified; Angioimmunoblastic T Cell Lymphoma; Enteropathy Associated T Cell Lymphoma; Hepatosplenic T Cell Lymphoma; Subcutaneous Panniculitis Like T Cell Lymphoma

Summary: t cell lymphoma is a heterogenic malignancy with poor outcome. five-year pfs and os of the patients recieved classic chop regimen(cyclophosphamide,vincristin,doxorubicin and predisone)is less than 30%.high dose intensive chemotherapy doesn't demonstrate better response. at present, there is no standardized treatment protocol for this kind of lymphoma. between 1994 and 1998,the scotland and newcastle lymphoma group prospectively collected data on newly diagnosed patients with enteropathy associated t-cell lymphoma (eatl)in the northern region of england and scotland,which is a rare and aggressive type of peripheral t-cell lymphoma.the novel regimen ive/mtx (ifosfamide, vincristine, etoposide/methotrexate)-asct was piloted for patients eligible for intensive treatment,followed by auto-stem cell transplantation.five-years pfs and os were 52% and 60% respectively, significantly improved compared with the historical group treated with anthracycline-based chemotherapy. the encouraged results were extended to the peripherial t cell lymphoma-non specified(ptcl-nos). past studies suggested pirarubicin was more active to the t cell lymphoma than doxorubicin in vitro based on its high concentration in tumor cells. clinical data also presented equivalent even superior efficacy of pirarubicin with lower toxicity than doxorubicin. the aim of our study is to compare the response and survival rate of ctop/ite/mtx (cyclophosphamide, vincristin,pirarubicin and predisone/ ifosfamide, pirarubicin, etoposide/methotrexate) with those of chop regimen,looking forward to its superiority in efficacy and safety for the de novo young patients with t cell lymphoma.


Eligibility criteria:
inclusion criteria: * pathologic verified mature t cell lymphoma,including alk-negative anaplastic large cell lymphoma,peripherial t cell lymphoma-non specific type,angioimmunoblastic t cell lymphoma,enteropathy associated t cell lymphoma and hepatosplenic t cell lymphoma * sgot/sgpt no more than 2 times of unl * serum creatinine no more than 1.5 times of unl * signed informed consent exclusion criteria: * woman in pregnancy or lactation * allergic to any intervention drug * insuitable to the study due to severe complication * enrolled to other study during the past 6 months